A parainfluenza-3 outbreak in a SCT unit: Sepsis with multi-organ failure and multiple co-pathogens are associated with increased mortality

Bone Marrow Transplantation

Volumn 46, Issue 12, 2011, Pages 1545-1550

  Hodson, A ^a   Kasliwal, M ^a   Streetly, M ^a   MacMahon, E ^b,c   Raj, K ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

bacterial co infection; haemopoietic SCT; parainfluenza; ribavirin

Indexed keywords

IMMUNOGLOBULIN; RIBAVIRIN;

ADULT; AEROSOL; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; EPIDEMIC; FEMALE; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION RISK; LOWER RESPIRATORY TRACT INFECTION; MALE; MIXED INFECTION; MORTALITY; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; PARAINFLUENZA VIRUS 3; PARAINFLUENZA VIRUS INFECTION; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE DRUG DOSE; VIRAL UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTIVIRAL AGENTS; DISEASE OUTBREAKS; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFECTION; INFECTION CONTROL; LUNG DISEASES; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PARAINFLUENZA VIRUS 3, HUMAN; RESPIROVIRUS INFECTIONS; RIBAVIRIN; SEPSIS; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84856079211     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.347     Document Type: Article

References (24)

1. Ljungman P, Ward KN, Crooks BN, Parker A, Martino R, Shaw PJ et al. Respiratory virus infections after stem cell transplantation: a prospective study for the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2001; 28: 479-484. (Pubitemid 33069626)
2. Schiffer J, Kirby K, Sandmaier B, Storb R, Corey L, Boeckh M. Timing and severity of community acquired respiratory infection after myeloablative versus non-myeloablative stem cell transplantation. Haematologica 2009; 94: 1101-1108.
3. Peck A, Englund J, Kuypers J, Guthrie K, Corey L, Morrow R et al. Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. Blood 2007; 110: 1681-1688. (Pubitemid 47443987)
4. Reed G, Jewett PH, Thompson J, Tollefson S, Wright PF. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children. J Infect Dis 1997; 175: 807-813. (Pubitemid 27142952)
5. Erard V, Chien JW, Kim HW, Nichols WG, Flowers ME, Martin PJ et al. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. J Infect Dis 2006; 193: 1619-1625. (Pubitemid 43839464)
6. Tyrell DAJ, Bynoe ML, Birkum K, Sutton RNP, Pereira MS. Inoculation of human volunteers with parainfluenza viruses 1 and 3 (HA2 and HA1). Br Med J 1959; 2: 909-911.
7. Laurichesse H, Dedman D, Watson JM, Zambon MC. Epidemiological features of parainfluenza virus infections: laboratory surveillance in England and Wales, 1975-1997. Eur J Epidemiol 1999; 15: 475-484. (Pubitemid 29320925)
8. Garrett Nichols W, Corey L, Gooley T, Davis C, Boeckh M. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001; 98: 573-578.
9. Lewis VA, Champlin R, Englund J, Couch R, Goodrich JM, Rolston K et al. Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipients. Clin Infect Dis 1996; 23: 1033-1037. (Pubitemid 26367489)
10. Wendt CH, Weisdorf DJ, Jordan MC, Balfour Jr HH, Hertz MI. Parainfluenza virus respiratory infection after bone marrow transplantation. N Engl J Med 1992; 326: 921-926.
11. Chakrabarti S, Avivi I, MacKinnon S, Ward K, Kottaridis PD, Osman H et al. Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality. Br J Haematol 2002; 119: 1125-1132. (Pubitemid 35463842)
12. Elizaga J, Olavarria E, Apperley J, Goldman J, Ward K. Parainfluenza virus 3 infection after stem cell transplant: relevance to outcome of rapid diagnosis and ribavirin treatment. Clin Infect Dis 2001; 32: 413-418. (Pubitemid 32173627)
13. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14. (Pubitemid 33152659)
14. Kuypers J, Campbell AP, Cent A, Corey L, Boeckh M. Comparison of conventional and molecular detection of respiratory viruses in hematopoietic cell transplant recipients. Transpl Infect Dis 2009; 11: 298-303.
15. Avadhanula V, Rodriguez C, DeVincenzo J, Wang Y, Webby R, Ulett G et al. Respiratory viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species-and cell type-dependant manner. J Virol 2006; 80: 1629-1636. (Pubitemid 43228704)
16. Dignan F, Alvares C, Riley U, Ethell M, Cunnigham D, Treleaven J et al. Parainfluenza type 3 infection post stem cell transplant: high prevalence but low mortality. J Hosp Inf 2006; 63: 452-458.
17. Chakrabarti S, Collingham K, Holder K, Oyaide S, Pillay D, Milligan D. Parainfluenza Virus Type 3 Infections in Hematopoietic Stem Cell Transplant Recipients: response to Ribavirin therapy. Clin Infect Dis 2000; 31: 1516-1518.
18. Henrickson KJ. Parainfluenza viruses. Clin Microbiol Rev 2003; 16: 242-264. (Pubitemid 36519811)
19. Brady MT, Evans J, Cuartas J. Survival and disinfection of parainfluenza viruses on environmental surfaces. Am J Infect Control 1990; 18: 18-23. (Pubitemid 20126002)
20. Stankova J, Carret AS, Moore D, McCusker C, Mitchell D, Davis M et al. Long-term therapy with aerosolized ribavirin for parainfluenza 3 virus respiratory tract infection in an infant with severe combined immunodeficiency. Pediatr transplant 2007; 11: 209-213. (Pubitemid 46174995)
21. Murrell M, Porotto M, Weber T, Greengard O, Moscona A. Mutations in human parainfluenza virus type 3 haemagglutinin-neuraminidase causing increased receptor binding activity and resistance to the transition state sialic acid analog 4-GUDANA (Zanamivir). J Virol 2003; 77: 309-317. (Pubitemid 36004971)
22. Alymova IV, Taylor G, Takimoto T, Lin TH, Chand P, Babu YS et al. Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo. Antimicrob Agents Chemother 2004; 48: 1495-1502. (Pubitemid 38544350)
23. Watanabe M, Mishin VP, Brown SA, Russell CJ, Boyd K, Babu YS et al. Effect of hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 on growth and pathogenicity of Sendai/human parainfluenza type 3 chimera virus in mice. Antimicrob Agents Chemother 2009; 53: 3942-3951.
24. McCann S, Byrne JL, Rivira M, Shaw P, Ribaud P, Sica S et al. Outbreaks of infectious diseases in stem cell transplant units: a silent cause of death for patients and transplant programmes. Bone Marrow Transplant 2004; 33: 519-529. (Pubitemid 38425783)